A large number of new drug technologies have emerged in the field of biomedicine in recent years, and nucleic acid drugs are a pillar of the third revolution of biotechnology. In the case of traditional small molecule chemical drugs in the critical period of "target exhaustion", nucleic acid pharmaceuticals provide a new direction and idea for drug research and development. Nucleic acid drugs are different from traditional small molecule or antibody drugs, and have unparalleled advantages in the number of drug targets, drug design cycle, target specificity, high efficiency and durability, etc., making it possible to actively design drugs to treat diseases at the nucleic acid level. Nucleic acid drugs are expected to open the third wave of modern new drugs after small molecule and antibody drugs.
Nucleic acid drugs are currently a hot area of research and development in the world. According to Evaluate Pharma's forecast, the global nucleic acid drug market will exceed US$8 billion in 2024, and the compound annual growth rate from 2018 to 2024 is expected to reach as high as 35%. At the same time, with the advent of the post-epidemic era, the "big reshuffle" of the global vaccine industry is coming. Under the pressure of epidemic prevention, countries are actively seeking breakthroughs in various cutting-edge vaccine technologies, and the vaccine industry has become a rapidly developing industry. In particular, mRNA vaccines have shined in this epidemic, further promoting the development of the industry.
In order to promote the integration of upstream and downstream industries and accelerate the transformation of scientific and technological achievements, Taas Labs held a series of activities such as CGT Asia and T-Bio, which were successfully held in Shanghai. The summit site was full of guests, 600+ industry experts came, and 40+ high-quality exhibitors set up booths to share professional technologies and solutions face- to - face . At the same time, the event brought together nearly 100 domestic and international leading pharmaceutical companies. Experts actively discussed hot topics and discussed opportunities for industrial innovation. On this basis, the Nucleic Acid Conference 2022 China Nucleic Acid Drug and New Vaccine Industry Conference hosted by Taas Labs will also be held in Wuhan, China from August 18th to 19th, 2022.
Some exciting topics:
—Advantages and development difficulties of nucleic acid drugs
—How to chemically modify the stability of nucleic acid drugs?
—Analysis and strategy of high-efficiency and long-acting mRNA delivery technology
—Research progress of antisense oligonucleotide ( ASO) drug
—In vitro activity verification and CMC design and development
— Technical barriers and cost control of siRNA/miRNA process
— Frontiers of mRNA COVID-19 Vaccine Technology
—How to lay out a considerable indication pipeline?
—Tumor vaccine clinical development strategy
—Disease-causing gene sequencing and third-generation sequencing technology
—Research and cases of vaccine adjuvant application
— GMP level raw material production and temperature and storage technology
— Domestic vaccine development layout and track strategy...
Participating companies in previous series of events:
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai Biomedical Industry Association, Johnson & Johnson, Takeda Pharmaceuticals, Arnold Pharmaceuticals, Amgen, BeiGene, Biogen, Novartis, Merck, MSD, Jiangsu Hengrui Medicine, Fosun Pharma, Henlius, Fosun Kate, Nanjing Legend, GenScript, CStone Pharmaceuticals, Genesis, Luye Group, Boan Bio, Gemma Gene, WuXi AppTec, WuXi Biologics, WuXi Juno, Sinopharm, Sunshine Guojian, CSPC, Cinda Bio , Shanghai Cell Therapy Group, Qilu Pharmaceutical, Yangzijiang Pharmaceutical, Simcere Pharmaceutical, BGI, Huada Genoin, China Resources Biomedicine, Nanjing Chia Tai Tianqing, Nuocheng Jianhua, Dongyao Pharmaceutical, Hebo Pharmaceutical, I-Mab Bio, Jimin Credible, Yunnan Watson Bio, Shanghai Yingpai Pharmaceutical, Quanxin Bio, Junshi Biology, Boshengji, Shasha Bio, Bangyao Biology, Blue Que Biology, Chongqing Precision, Beiheng Biology, Xinghande, Immune Onco, Yiming Cell, Stardust Bio, Newphth, Hittech, Anke Bio, Runze Bio, Jingding, Tigermed, IQVIA, etc.
Nucleic Acid Convergence · 2022 China Nucleic Acid Drug and New Vaccine Industry Conference will integrate high-quality resources at home and abroad and the whole industry, grasp the industry trend from a professional perspective and develop a vision, and set off an "ideological storm". In this conference, more than 30 domestic and foreign industry leaders will share their experience, insights and application cases, interpret the latest trends and ideas in the industry, and gain insight into industry development and new trends in the industry . Nucleic Acid Convergence · 2022 China Nucleic Acid Drug and New Vaccine Industry Conference will focus deeply on the field of nucleic acid and vaccines, creating an industry-leading event, committed to promoting innovation and development of the biotechnology industry, and bringing you a brand new experience of thought storms.